SCHEMBL667481

SCHEMBL667481

OCCn1cnc2cnc3ccccc3c21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
PDPK1 O15530 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
ATM Q13315 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
TDO2 P48775 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
EGLN3 Q9H6Z9 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL22718534 0.98 DPP4 (0.45) DPP4DPP8TDP1PDPK1SMN1; SMN2
Water SCHEMBL29438456 0.98 DPP4 (0.45) DPP4DPP8TDP1PDPK1SMN1; SMN2
SCHEMBL1335070 0.90 POLB (0.41) TDP1SMN1; SMN2TLR7POLBCYP1A2
SCHEMBL17344730 0.88 MPO (0.42) SMN1; SMN2TLR7POLBCYP1A2CYP2D6
SCHEMBL9603134 0.82 HTT (0.59) TDP1SMN1; SMN2POLBTHRBMEN1
SCHEMBL2029970 0.82 PDE4A (0.47) TDP1SMN1; SMN2TLR7POLBCYP1A2
SCHEMBL30930028 0.82 CYP1A2 (0.42) TDP1SMN1; SMN2POLBCYP1A2CYP2D6
SCHEMBL29265624 0.82 CYP1A2 (0.42) TDP1SMN1; SMN2POLBCYP1A2CYP2D6
SCHEMBL9601955 0.81 SMN1; SMN2 (0.42) TDP1SMN1; SMN2TLR7POLBLMNA
SCHEMBL6105595 0.81 STAT3 (0.41) TDP1SMN1; SMN2TLR7POLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998972-B2 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2011-08-16 US claimed
JP-4707389-B2 2011-06-22 JP claimed
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2005-11-03 US claimed
EP-1509521-A2 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2005-03-02 EP claimed
WO-2003097641-A2 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2003-11-27 WO claimed
EP-0708773-A1 FUSED CYCLOALKYLIMIDAZOPYRIDINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-05-01 EP claimed
WO-1995002598-A1 FUSED CYCLOALKYLIMIDAZOPYRIDINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-01-26 WO claimed
WO-2023203135-A1 IMPROVED RADIOLABELLED ANTIBODY PRECIRIX N.V. (BE) 2023-10-26 WO disclosed
CN-114929265-A Personalized tumor vaccine and use thereof for cancer immunotherapy NE1股份有限公司 2022-08-19 CN disclosed
US-11266746-B2 Therapeutic antitumor combination of a TLR4 ligand with other treatments The United Slates of America, as represented by the Secretary, Department of Health and Human Services (US) 2022-03-08 US disclosed
EP-3294295-B1 TLR7 AND/OR TLR8 AGONISTS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS INST NAT SANTE RECH MED (FR) 2021-08-04 EP disclosed
WO-2021116420-A1 USE OF TLR7 AND/OR TLR8 AGONISTS FOR THE TREATMENT OF LEPTOSPIROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2021-06-17 WO disclosed
EP-3648791-A1 NOVEL NUCLEIC ACID MOLECULES CureVac AG (DE) 2020-05-13 EP disclosed
WO-1995002598-A1 FUSED CYCLOALKYLIMIDAZOPYRIDINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-01-26 WO disclosed
EP-0310950-B1 Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes RIKER LABORATORIES, INC. (US) 1993-01-13 EP disclosed
EP-0145340-B1 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines RIKER LABORATORIES, INC. (US) 1990-01-24 EP disclosed
EP-0310950-A1 Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes RIKER LABORATORIES, INC. (US) 1989-04-12 EP disclosed
US-4698348-A 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents RIKER LABORATORIES, INC. (US) 1987-10-06 US disclosed
US-4689338-A 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use RIKER LABORATORIES, INC. (US) 1987-08-25 US disclosed
EP-0145340-A2 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines RIKER LABORATORIES, INC. (US) 1985-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases ABL1, PRKCA, PRKCQ DPP4 2977/4885DPP8 3333/4885TDP1 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.